has entered a new collaborative research agreement with Roche
for the continued development of novel chelating agents designed by Macrocyclics for Roche's applications. The collaboration aims to speed up the clinical development process. The new project will build on established progress related to lead-212 (212Pb) and novel chelate architecture for radioimmunotherapy.
"We are privileged to be working with the world leader in oncology and antibody technology and are excited to contribute in the development of powerful new therapies based on lead-212," said Garry Kiefer, chief executive officer of Macrocyclics.